Lars Jøran Kjerpeseth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Lars Jøran Kjerpeseth has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
- Inger Ariansen
Norwegian Institute of Public Health
5 shared publications - Øystein Karlstad
Department of Chronic Diseases Norwegian Institute of Public Health Oslo Norway
5 shared publications Eva Skovlund
Department of Chronic Diseases and Ageing, Norwegian Institute of Public Health, Oslo, Norway
4 shared publicationsHanne Ellekjær
Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway
4 shared publications- Kari Furu
Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway
4 shared publications Randi Selmer
Department of Chronic Diseases and Ageing, Norwegian Institute of Public Health, Oslo, Norway
4 shared publications
Latest Publications
- 5 May 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (7) , 6312-6323
Clinical Characteristics of Users of Weight Loss Drugs: Population‐Based Case–Control Study
Objectives: To investigate the clinical characteristics of weight loss drugs (WLDs) users in Norway. Design: Nested population‐based case–control study. Setting: Nationwide healthcare registries with data on dispensed medications and healthcare diagnoses. Participants: Individuals aged 18–74 years initiating WLDs during 2023–2024, categorised by drugs: semaglutide (only Wegovy), liraglutide (only Saxenda), tirzepatide, bupropion‐naltrexone or orlistat. Each WLD user was matched with five age‐ and sex‐matched population controls. Main Outcome Measures: Comorbidities diagnosed in the 2 years preceding initiation of WLD use and comedications dispensed in the preceding year, analysed using conditional logistic regression. Results: 150 036 individuals initiated semaglutide, 4603 liraglutide, 3596 tirzepatide, 31 172 bupropion–naltrexone and 1411 orlistat. Among WLD users, 71%–78% were registered with at least one comorbidity, compared with 49%–51% in controls. Nineteen percent to 24% of WLD users had four or more comorbidities. Hypertension was observed among 32%–38% of WLD users versus 17%–20% of controls; hyperlipidaemias: 20%–24% versus 12%–15%; sleep apnoea: 7%–11% versus 2%–3%; back pain: 15%–20% versus 10%–11%; opioids: 24%–30% versus 13%–15%; antidepressants: 20%–24% versus 10%–11%. Having only a basic level of education (≤ 10 years) was more common among WLD users than among controls (20%–28% vs. 17%), except for tirzepatide users, where the education level distribution was as for controls. Conclusions: WLD use is rapidly increasing, with users often having complex comorbidities. Understanding these patterns helps ensure that medications are used as intended. Like other countries with universal health systems, Norway must address the high cost of obesity treatments and mitigate health disparities to ensure access for those most likely to benefit.
- 5 May 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (7) , 6312-6323
Clinical Characteristics of Users of Weight Loss Drugs: Population‐Based Case–Control Study
Objectives: To investigate the clinical characteristics of weight loss drugs (WLDs) users in Norway. Design: Nested population‐based case–control study. Setting: Nationwide healthcare registries with data on dispensed medications and healthcare diagnoses. Participants: Individuals aged 18–74 years initiating WLDs during 2023–2024, categorised by drugs: semaglutide (only Wegovy), liraglutide (only Saxenda), tirzepatide, bupropion‐naltrexone or orlistat. Each WLD user was matched with five age‐ and sex‐matched population controls. Main Outcome Measures: Comorbidities diagnosed in the 2 years preceding initiation of WLD use and comedications dispensed in the preceding year, analysed using conditional logistic regression. Results: 150 036 individuals initiated semaglutide, 4603 liraglutide, 3596 tirzepatide, 31 172 bupropion–naltrexone and 1411 orlistat. Among WLD users, 71%–78% were registered with at least one comorbidity, compared with 49%–51% in controls. Nineteen percent to 24% of WLD users had four or more comorbidities. Hypertension was observed among 32%–38% of WLD users versus 17%–20% of controls; hyperlipidaemias: 20%–24% versus 12%–15%; sleep apnoea: 7%–11% versus 2%–3%; back pain: 15%–20% versus 10%–11%; opioids: 24%–30% versus 13%–15%; antidepressants: 20%–24% versus 10%–11%. Having only a basic level of education (≤ 10 years) was more common among WLD users than among controls (20%–28% vs. 17%), except for tirzepatide users, where the education level distribution was as for controls. Conclusions: WLD use is rapidly increasing, with users often having complex comorbidities. Understanding these patterns helps ensure that medications are used as intended. Like other countries with universal health systems, Norway must address the high cost of obesity treatments and mitigate health disparities to ensure access for those most likely to benefit.
- Open Access
- 28 February 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
A comprehensive nationwide registry study of noncommunicable disease comorbidities and death in cancer patients in Norway—the NCDNOR project
Noncommunicable disease (NCD) comorbidities are common in cancer patients due to shared risk factors, but few studies have mapped their occurrence across cancer types using detailed national data. In this nationwide cohort study, we used data from Norwegian mandatory health registries to comprehensively describe NCD comorbidities at and after cancer diagnosis of 19 cancers. We included 269,956 adults registered with a first cancer in the Cancer Registry of Norway 2009–2019. Comorbidities included second cancers, cardiovascular diseases (CVDs), chronic obstructive pulmonary disease, diabetes and mental health disorders (MDs). We used intersection diagrams to examine NCD comorbidity patterns at first cancer diagnosis, and multi-state models to estimate five-year post-cancer probabilities of NCD comorbidities and death. We also provide a publicly available online application [ https://ncdapp.onrender.com/ ] with additional results and details. Comorbidity prevalence at cancer diagnosis ranged from 35% (skin cancer) to 83% (lung cancer). CVD was most prevalent, usually co-occurring with MDs or diabetes. Lowest prevalences were found for younger patients and women. Conditioning on surviving five years, comorbidity probability exceeded 50% in all sites. Our findings show substantial comorbidity burden in cancer patients, varying by cancer site, age, and sex. Knowledge of these patterns could improve NCD prevention, treatment and surveillance.
- 28 February 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessA comprehensive nationwide registry study of noncommunicable disease comorbidities and death in cancer patients in Norway—the NCDNOR project
Noncommunicable disease (NCD) comorbidities are common in cancer patients due to shared risk factors, but few studies have mapped their occurrence across cancer types using detailed national data. In this nationwide cohort study, we used data from Norwegian mandatory health registries to comprehensively describe NCD comorbidities at and after cancer diagnosis of 19 cancers. We included 269,956 adults registered with a first cancer in the Cancer Registry of Norway 2009–2019. Comorbidities included second cancers, cardiovascular diseases (CVDs), chronic obstructive pulmonary disease, diabetes and mental health disorders (MDs). We used intersection diagrams to examine NCD comorbidity patterns at first cancer diagnosis, and multi-state models to estimate five-year post-cancer probabilities of NCD comorbidities and death. We also provide a publicly available online application [ https://ncdapp.onrender.com/ ] with additional results and details. Comorbidity prevalence at cancer diagnosis ranged from 35% (skin cancer) to 83% (lung cancer). CVD was most prevalent, usually co-occurring with MDs or diabetes. Lowest prevalences were found for younger patients and women. Conditioning on surviving five years, comorbidity probability exceeded 50% in all sites. Our findings show substantial comorbidity burden in cancer patients, varying by cancer site, age, and sex. Knowledge of these patterns could improve NCD prevention, treatment and surveillance.
- Open Access
CLINICAL CHARACTERISTICS OF USERS OF WEIGHT LOSS DRUGS: POPULATION-BASED CASE-CONTROL STUDY
Objectives: To investigate clinical characteristics of users of weight loss drugs in Norway. Design: Nested population-based case control study Setting: Nationwide healthcare registers in Norway with information on all dispensed medications linked to contacts with primary and specialist healthcare services. Participants: All individuals aged 18-74 years with first dispensing of a weight loss drug (WLD) in 2023–2024, classified as initiators of 1) semaglutide (only Wegovy), 2) liraglutide (only Saxenda), 3) tirzepatide, 4) bupropion–naltrexone, or 5) orlistat. We matched each WLD user by sex and age to five controls randomly selected from the general Norwegian population. Main outcome measures: Type and count of number of comorbidities diagnosed in the two years preceding initiation of WLD use, comedications dispensed in the preceding year, and any previous bariatric surgery. Differences between WLD users and population controls were estimated using conditional logistic regression adjusted for country of birth and education level. Results: During 2023-24, 150,036 individuals initiated semaglutide, 4,603 liraglutide, 3,596 tirzepatide, 31,172 bupropion–naltrexone, and 1,411 orlistat. Among WLD users, 22-29% were registered without any of the pre-defined comorbidities, compared to around half of population controls. Comorbidities and comedications were generally observed at similar proportions in the different WLD user groups, but at much lower proportion for controls: hypertension: 32-38% of WLD users vs. 17-20% of controls; hyperlipidaemias: 20-24% vs. 12-15%; sleep apnoea: 7-11% vs. 2-3%; back pain: 15-20% vs. 10-11%; opioids: 24-30%vs. 13-15%; antidepressants: 20-24%vs. 10-11%. Conclusions: Like other countries, Norway faces the challenge of costly pharmacological obesity treatment, and the need for measures to mitigate increasing socioeconomic health disparities to ensure access to obesity treatment for those most likely to benefit including persons with multimorbidity. What is already known on this topic: Obesity is increasing worldwide and is associated with increased risk of multimorbidity. The available treatment options for obesity have been rapidly and substantially transformed by the availability of new weight loss drugs. What this study adds: This nested case-control study within the Norwegian population examined clinical characteristics of new users of five weight loss drugs: semaglutide, liraglutide, tirzepatide, bupropion–naltrexone, and orlistat. The study identified a higher proportion of weight loss drugs users with cardiovascular, endocrine, mental, and other health conditions, as well as increased usage of cardiovascular, nervous system, and chronic pain medications, compared to the general population. The majority of WLD users had high levels of multimorbidity and medication use compared to controls. Approximately 1 in 5 WLD users had no registered comorbidity in either primary or specialist health care systems. Additionally, we noted differences in sociodemographic factors between users and population controls, such as lower education levels among WLD users. The rapidly expanding use of weight loss drugs necessitates close attention from public health authorities.
Open AccessCLINICAL CHARACTERISTICS OF USERS OF WEIGHT LOSS DRUGS: POPULATION-BASED CASE-CONTROL STUDY
Objectives: To investigate clinical characteristics of users of weight loss drugs in Norway. Design: Nested population-based case control study Setting: Nationwide healthcare registers in Norway with information on all dispensed medications linked to contacts with primary and specialist healthcare services. Participants: All individuals aged 18-74 years with first dispensing of a weight loss drug (WLD) in 2023–2024, classified as initiators of 1) semaglutide (only Wegovy), 2) liraglutide (only Saxenda), 3) tirzepatide, 4) bupropion–naltrexone, or 5) orlistat. We matched each WLD user by sex and age to five controls randomly selected from the general Norwegian population. Main outcome measures: Type and count of number of comorbidities diagnosed in the two years preceding initiation of WLD use, comedications dispensed in the preceding year, and any previous bariatric surgery. Differences between WLD users and population controls were estimated using conditional logistic regression adjusted for country of birth and education level. Results: During 2023-24, 150,036 individuals initiated semaglutide, 4,603 liraglutide, 3,596 tirzepatide, 31,172 bupropion–naltrexone, and 1,411 orlistat. Among WLD users, 22-29% were registered without any of the pre-defined comorbidities, compared to around half of population controls. Comorbidities and comedications were generally observed at similar proportions in the different WLD user groups, but at much lower proportion for controls: hypertension: 32-38% of WLD users vs. 17-20% of controls; hyperlipidaemias: 20-24% vs. 12-15%; sleep apnoea: 7-11% vs. 2-3%; back pain: 15-20% vs. 10-11%; opioids: 24-30%vs. 13-15%; antidepressants: 20-24%vs. 10-11%. Conclusions: Like other countries, Norway faces the challenge of costly pharmacological obesity treatment, and the need for measures to mitigate increasing socioeconomic health disparities to ensure access to obesity treatment for those most likely to benefit including persons with multimorbidity. What is already known on this topic: Obesity is increasing worldwide and is associated with increased risk of multimorbidity. The available treatment options for obesity have been rapidly and substantially transformed by the availability of new weight loss drugs. What this study adds: This nested case-control study within the Norwegian population examined clinical characteristics of new users of five weight loss drugs: semaglutide, liraglutide, tirzepatide, bupropion–naltrexone, and orlistat. The study identified a higher proportion of weight loss drugs users with cardiovascular, endocrine, mental, and other health conditions, as well as increased usage of cardiovascular, nervous system, and chronic pain medications, compared to the general population. The majority of WLD users had high levels of multimorbidity and medication use compared to controls. Approximately 1 in 5 WLD users had no registered comorbidity in either primary or specialist health care systems. Additionally, we noted differences in sociodemographic factors between users and population controls, such as lower education levels among WLD users. The rapidly expanding use of weight loss drugs necessitates close attention from public health authorities.
- Open Access
- 24 July 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (10)
Timing of stroke risk reassessment in atrial fibrillation patients with a CHA2DS2-VA score of 0 or 1: the Norwegian AFNOR study
Aims: Stroke risk in atrial fibrillation (AF) patients increases over time, but the optimal reassessment interval remains unclear. This study evaluated changes in the CHA2DS2-VA score in AF patients with low (score 0) or intermediate (score 1) stroke risk and explored appropriate reassessment intervals. Methods and results: Using Norwegian national registries (2011–18), 40 782 individuals with incident AF aged ≥18 years and a low or intermediate CHA2DS2-VA score were identified. Patients were followed from first AF diagnosis until an increase in the CHA2DS2-VA score, and the proportion with increased score was assessed across age groups. The number needed to reassess to detect one new CHA2DS2-VA risk factor was calculated at different time intervals after AF diagnosis. The CHA2DS2-VA score increased in 50% of patients after a median follow-up of 1.7 years. The proportion of patients with an increased CHA2DS2-VA score was 19% at 6 months, 25% at 1 year, and 40% at 3 years after AF diagnosis. At 1 year, the proportion of patients with a new risk factor was lower in those aged 18–44 years (8%) and 45–54 years (14%) compared to those aged >55 years (30%), with the number needed to reassess at 1 year being 12, 7, and 3 patients, respectively. Conclusion: New risk factors emerged in half of AF patients within 1.7 years. Age-specific differences underscore the need for tailored reassessment, suggesting a shorter interval of 6 months for patients ≥55 years and 1 year for those <55 years and routinely at age 65 and 75 years.
- 24 July 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (10)
Open AccessTiming of stroke risk reassessment in atrial fibrillation patients with a CHA2DS2-VA score of 0 or 1: the Norwegian AFNOR study
Aims: Stroke risk in atrial fibrillation (AF) patients increases over time, but the optimal reassessment interval remains unclear. This study evaluated changes in the CHA2DS2-VA score in AF patients with low (score 0) or intermediate (score 1) stroke risk and explored appropriate reassessment intervals. Methods and results: Using Norwegian national registries (2011–18), 40 782 individuals with incident AF aged ≥18 years and a low or intermediate CHA2DS2-VA score were identified. Patients were followed from first AF diagnosis until an increase in the CHA2DS2-VA score, and the proportion with increased score was assessed across age groups. The number needed to reassess to detect one new CHA2DS2-VA risk factor was calculated at different time intervals after AF diagnosis. The CHA2DS2-VA score increased in 50% of patients after a median follow-up of 1.7 years. The proportion of patients with an increased CHA2DS2-VA score was 19% at 6 months, 25% at 1 year, and 40% at 3 years after AF diagnosis. At 1 year, the proportion of patients with a new risk factor was lower in those aged 18–44 years (8%) and 45–54 years (14%) compared to those aged >55 years (30%), with the number needed to reassess at 1 year being 12, 7, and 3 patients, respectively. Conclusion: New risk factors emerged in half of AF patients within 1.7 years. Age-specific differences underscore the need for tailored reassessment, suggesting a shorter interval of 6 months for patients ≥55 years and 1 year for those <55 years and routinely at age 65 and 75 years.
- Open Access
- 8 April 2024
- Published by Springer Nature in Nature Medicine
- Vol. 30 (5) , 1416-1423
Maternal diabetes and risk of attention-deficit/hyperactivity disorder in offspring in a multinational cohort of 3.6 million mother–child pairs
Previous studies report an association between maternal diabetes mellitus (MDM) and attention-deficit/hyperactivity disorder (ADHD), often overlooking unmeasured confounders such as shared genetics and environmental factors. We therefore conducted a multinational cohort study with linked mother–child pairs data in Hong Kong, New Zealand, Taiwan, Finland, Iceland, Norway and Sweden to evaluate associations between different MDM (any MDM, gestational diabetes mellitus (GDM) and pregestational diabetes mellitus (PGDM)) and ADHD using Cox proportional hazards regression. We included over 3.6 million mother–child pairs between 2001 and 2014 with follow-up until 2020. Children who were born to mothers with any type of diabetes during pregnancy had a higher risk of ADHD than unexposed children (pooled hazard ratio (HR) = 1.16, 95% confidence interval (CI) = 1.08-1.24). Higher risks of ADHD were also observed for both GDM (pooled HR = 1.10, 95% CI = 1.04-1.17) and PGDM (pooled HR = 1.39, 95% CI = 1.25-1.55). However, siblings with discordant exposure to GDM in pregnancy had similar risks of ADHD (pooled HR = 1.05, 95% CI = 0.94-1.17), suggesting potential confounding by unmeasured, shared familial factors. Our findings indicate that there is a small-to-moderate association between MDM and ADHD, whereas the association between GDM and ADHD is unlikely to be causal. This finding contrast with previous studies, which reported substantially higher risk estimates, and underscores the need to reevaluate the precise roles of hyperglycemia and genetic factors in the relationship between MDM and ADHD.
- 8 April 2024
- Published by Springer Nature in Nature Medicine
- Vol. 30 (5) , 1416-1423
Open AccessMaternal diabetes and risk of attention-deficit/hyperactivity disorder in offspring in a multinational cohort of 3.6 million mother–child pairs
Previous studies report an association between maternal diabetes mellitus (MDM) and attention-deficit/hyperactivity disorder (ADHD), often overlooking unmeasured confounders such as shared genetics and environmental factors. We therefore conducted a multinational cohort study with linked mother–child pairs data in Hong Kong, New Zealand, Taiwan, Finland, Iceland, Norway and Sweden to evaluate associations between different MDM (any MDM, gestational diabetes mellitus (GDM) and pregestational diabetes mellitus (PGDM)) and ADHD using Cox proportional hazards regression. We included over 3.6 million mother–child pairs between 2001 and 2014 with follow-up until 2020. Children who were born to mothers with any type of diabetes during pregnancy had a higher risk of ADHD than unexposed children (pooled hazard ratio (HR) = 1.16, 95% confidence interval (CI) = 1.08-1.24). Higher risks of ADHD were also observed for both GDM (pooled HR = 1.10, 95% CI = 1.04-1.17) and PGDM (pooled HR = 1.39, 95% CI = 1.25-1.55). However, siblings with discordant exposure to GDM in pregnancy had similar risks of ADHD (pooled HR = 1.05, 95% CI = 0.94-1.17), suggesting potential confounding by unmeasured, shared familial factors. Our findings indicate that there is a small-to-moderate association between MDM and ADHD, whereas the association between GDM and ADHD is unlikely to be causal. This finding contrast with previous studies, which reported substantially higher risk estimates, and underscores the need to reevaluate the precise roles of hyperglycemia and genetic factors in the relationship between MDM and ADHD.
- 23 January 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 102 (2) , e207996
Comparative Risk of Major Congenital Malformations With Antiseizure Medication Combinations vs Valproate Monotherapy in Pregnancy
Valproate should be avoided in pregnancy, but it is the most effective drug for generalized epilepsies. Alternative treatment may require combinations of other drugs. Our objectives were to describe first trimester use of antiseizure medication (ASM) combinations that are relevant alternatives to valproate and determine whether specific combinations were associated with a lower risk of major congenital malformations (MCM) compared with valproate monotherapy. We conducted a population-based cohort study using linked national registers from Denmark, Finland, Iceland, Norway, and Sweden and administrative health care data from the United States and New South Wales, Australia. We described first trimester use of ASM combinations among pregnant people with epilepsy from 2000 to 2020. We compared the risk of MCM after first trimester exposure to ASM combinations vs valproate monotherapy and low-dose valproate plus lamotrigine or levetiracetam vs high-dose valproate (≥1,000 mg/d). We used log-binomial regression with propensity score weights to calculate adjusted risk ratios (aRRs) and 95% CIs for each dataset. Results were pooled using fixed-effects meta-analysis. Among 50,905 pregnancies in people with epilepsy identified from 7.8 million total pregnancies, 788 used lamotrigine and levetiracetam, 291 used lamotrigine and topiramate, 208 used levetiracetam and topiramate, 80 used lamotrigine and zonisamide, and 91 used levetiracetam and zonisamide. After excluding pregnancies with use of other ASMs, known teratogens, or a child diagnosed with MCM of infectious or genetic cause, we compared 587 exposed to lamotrigine-levetiracetam duotherapy and 186 exposed to lamotrigine-topiramate duotherapy with 1959 exposed to valproate monotherapy. Pooled aRRs were 0.41 (95% CI 0.24-0.69) and 1.26 (0.71-2.23), respectively. Duotherapy combinations containing low-dose valproate were infrequent, and comparisons with high-dose valproate monotherapy were inconclusive but suggested a lower risk for combination therapy. Other combinations were too rare for comparative safety analyses. Lamotrigine-levetiracetam duotherapy in first trimester was associated with a 60% lower risk of MCM than valproate monotherapy, while lamotrigine-topiramate was not associated with a reduced risk. Duotherapy with lamotrigine and levetiracetam may be favored to treat epilepsy in people with childbearing potential compared with valproate regarding MCM, but whether this combination is as effective as valproate remains to be determined. This study provides Class II evidence that in people with epilepsy treated in the first trimester of pregnancy, the risk of major congenital malformations is lower with lamotrigine-levetiracetam duotherapy than with valproate alone, but similar with lamotrigine-topiramate.
- 23 January 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 102 (2) , e207996
Comparative Risk of Major Congenital Malformations With Antiseizure Medication Combinations vs Valproate Monotherapy in Pregnancy
Valproate should be avoided in pregnancy, but it is the most effective drug for generalized epilepsies. Alternative treatment may require combinations of other drugs. Our objectives were to describe first trimester use of antiseizure medication (ASM) combinations that are relevant alternatives to valproate and determine whether specific combinations were associated with a lower risk of major congenital malformations (MCM) compared with valproate monotherapy. We conducted a population-based cohort study using linked national registers from Denmark, Finland, Iceland, Norway, and Sweden and administrative health care data from the United States and New South Wales, Australia. We described first trimester use of ASM combinations among pregnant people with epilepsy from 2000 to 2020. We compared the risk of MCM after first trimester exposure to ASM combinations vs valproate monotherapy and low-dose valproate plus lamotrigine or levetiracetam vs high-dose valproate (≥1,000 mg/d). We used log-binomial regression with propensity score weights to calculate adjusted risk ratios (aRRs) and 95% CIs for each dataset. Results were pooled using fixed-effects meta-analysis. Among 50,905 pregnancies in people with epilepsy identified from 7.8 million total pregnancies, 788 used lamotrigine and levetiracetam, 291 used lamotrigine and topiramate, 208 used levetiracetam and topiramate, 80 used lamotrigine and zonisamide, and 91 used levetiracetam and zonisamide. After excluding pregnancies with use of other ASMs, known teratogens, or a child diagnosed with MCM of infectious or genetic cause, we compared 587 exposed to lamotrigine-levetiracetam duotherapy and 186 exposed to lamotrigine-topiramate duotherapy with 1959 exposed to valproate monotherapy. Pooled aRRs were 0.41 (95% CI 0.24-0.69) and 1.26 (0.71-2.23), respectively. Duotherapy combinations containing low-dose valproate were infrequent, and comparisons with high-dose valproate monotherapy were inconclusive but suggested a lower risk for combination therapy. Other combinations were too rare for comparative safety analyses. Lamotrigine-levetiracetam duotherapy in first trimester was associated with a 60% lower risk of MCM than valproate monotherapy, while lamotrigine-topiramate was not associated with a reduced risk. Duotherapy with lamotrigine and levetiracetam may be favored to treat epilepsy in people with childbearing potential compared with valproate regarding MCM, but whether this combination is as effective as valproate remains to be determined. This study provides Class II evidence that in people with epilepsy treated in the first trimester of pregnancy, the risk of major congenital malformations is lower with lamotrigine-levetiracetam duotherapy than with valproate alone, but similar with lamotrigine-topiramate.
- Open Access
- 22 November 2023
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 207, 111025
Prevalence and treatment of gestational diabetes in Norway 2010–2020
- 22 November 2023
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 207, 111025
Open AccessPrevalence and treatment of gestational diabetes in Norway 2010–2020
- 21 June 2023
- Published by American Diabetes Association in Diabetes Care
- Vol. 46 (8) , 1556-1564
Metformin Versus Insulin and Risk of Major Congenital Malformations in Pregnancies With Type 2 Diabetes: A Nordic Register-Based Cohort Study
OBJECTIVE: To assess the risk of major congenital malformations with metformin versus insulin in pregnancies with type 2 diabetes.RESEARCH DESIGN AND METHODS: This cohort study used four Nordic countries’ nationwide registers of live and stillborn infants exposed to metformin or insulin during first trimester organogenesis. Main exclusion criteria were type 1 diabetes, polycystic ovary syndrome, fertility treatment, and exposure to other diabetes drugs. Adjusted risk ratios (RRs) and 95% CIs were estimated for any and cardiac malformations.RESULTS: Of 3,734,125 infants in the source population, 25,956 were exposed to metformin or insulin in the first trimester, and 4,023 singleton infants were included. A malformation was diagnosed in 147 (4.7%) of 3,145 infants with exposure to any metformin (alone or in addition to insulin) and 50 (5.7%) of 878 infants with exposure to insulin alone (RR 0.84, 95% CI 0.46–1.54). Among 2,852 infants exposed to metformin alone and 293 infants exposed to metformin in addition to insulin 127 (4.4%) and 20 (6.8%), respectively, had a malformation. The adjusted risk was not increased for either metformin alone (0.83, 0.44–1.58) or both metformin and insulin (0.98, 0.56–1.69) versus insulin alone. Corresponding RRs for cardiac malformations were 1.01 (0.55–1.84) for any metformin, 0.92 (0.47–1.81) for metformin alone, and 1.72 (0.76–3.91) for both metformin and insulin.CONCLUSIONS: No evidence of an increased malformation risk with metformin versus insulin in the first trimester was found. Results should be interpreted with caution since information on glycemic control was missing.
- 21 June 2023
- Published by American Diabetes Association in Diabetes Care
- Vol. 46 (8) , 1556-1564
Metformin Versus Insulin and Risk of Major Congenital Malformations in Pregnancies With Type 2 Diabetes: A Nordic Register-Based Cohort Study
OBJECTIVE: To assess the risk of major congenital malformations with metformin versus insulin in pregnancies with type 2 diabetes.RESEARCH DESIGN AND METHODS: This cohort study used four Nordic countries’ nationwide registers of live and stillborn infants exposed to metformin or insulin during first trimester organogenesis. Main exclusion criteria were type 1 diabetes, polycystic ovary syndrome, fertility treatment, and exposure to other diabetes drugs. Adjusted risk ratios (RRs) and 95% CIs were estimated for any and cardiac malformations.RESULTS: Of 3,734,125 infants in the source population, 25,956 were exposed to metformin or insulin in the first trimester, and 4,023 singleton infants were included. A malformation was diagnosed in 147 (4.7%) of 3,145 infants with exposure to any metformin (alone or in addition to insulin) and 50 (5.7%) of 878 infants with exposure to insulin alone (RR 0.84, 95% CI 0.46–1.54). Among 2,852 infants exposed to metformin alone and 293 infants exposed to metformin in addition to insulin 127 (4.4%) and 20 (6.8%), respectively, had a malformation. The adjusted risk was not increased for either metformin alone (0.83, 0.44–1.58) or both metformin and insulin (0.98, 0.56–1.69) versus insulin alone. Corresponding RRs for cardiac malformations were 1.01 (0.55–1.84) for any metformin, 0.92 (0.47–1.81) for metformin alone, and 1.72 (0.76–3.91) for both metformin and insulin.CONCLUSIONS: No evidence of an increased malformation risk with metformin versus insulin in the first trimester was found. Results should be interpreted with caution since information on glycemic control was missing.
- Open Access
- 26 October 2022
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 14, 1193-1204
Prevalence and Incidence Rates of Atrial Fibrillation in Denmark 2004–2018
Purpose: To estimate the prevalence and incidence of atrial fibrillation (AF) in Denmark during 2004– 2018 and to investigate whether methodological choices influence these estimates. Patients and Methods: A register-based cohort study was conducted of all individuals aged ≥ 18 years in Denmark 2004– 2018. The cumulative prevalence of AF at the end of the study period was calculated as the number of AF cases alive with at least one inpatient or two outpatient diagnoses during 1994– 2018 divided by the number of Danish residents in 2018. Incidence rates were calculated as the number of annual AF cases with no previous diagnosis in the past 10 years (ie, a 10-year washout period) divided by the person-time contributed by the population free of AF on 1 January in the same calendar year. Furthermore, the influence of varying case definitions was investigated. Results: The cumulative prevalence of AF was 3.0% in 2018. The incidence rate increased from 391 to 481 per 100,000 person-years (PYs) from 2004 to 2015 (1.7% average annual increase) after which it declined to 367 per 100,000 PYs in 2018 (8.5% average annual decrease). This pattern was observed in both sexes irrespective of age. Methodological choices, particularly the case definition’s strictness and the length of the washout period, had a substantial influence on the reported estimates. Conclusion: The cumulative prevalence of AF is currently around 3.0% in the Danish population, but the incidence has declined since 2015. As these estimates are influenced by methodological choices, future studies should strive for precise reporting of study methodology.
- 26 October 2022
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 14, 1193-1204
Open AccessPrevalence and Incidence Rates of Atrial Fibrillation in Denmark 2004–2018
Purpose: To estimate the prevalence and incidence of atrial fibrillation (AF) in Denmark during 2004– 2018 and to investigate whether methodological choices influence these estimates. Patients and Methods: A register-based cohort study was conducted of all individuals aged ≥ 18 years in Denmark 2004– 2018. The cumulative prevalence of AF at the end of the study period was calculated as the number of AF cases alive with at least one inpatient or two outpatient diagnoses during 1994– 2018 divided by the number of Danish residents in 2018. Incidence rates were calculated as the number of annual AF cases with no previous diagnosis in the past 10 years (ie, a 10-year washout period) divided by the person-time contributed by the population free of AF on 1 January in the same calendar year. Furthermore, the influence of varying case definitions was investigated. Results: The cumulative prevalence of AF was 3.0% in 2018. The incidence rate increased from 391 to 481 per 100,000 person-years (PYs) from 2004 to 2015 (1.7% average annual increase) after which it declined to 367 per 100,000 PYs in 2018 (8.5% average annual decrease). This pattern was observed in both sexes irrespective of age. Methodological choices, particularly the case definition’s strictness and the length of the washout period, had a substantial influence on the reported estimates. Conclusion: The cumulative prevalence of AF is currently around 3.0% in the Danish population, but the incidence has declined since 2015. As these estimates are influenced by methodological choices, future studies should strive for precise reporting of study methodology.
- Open Access
- 10 March 2022
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 43 (37) , 3528-3538
Oral anticoagulants in patients with atrial fibrillation at low stroke risk: a multicentre observational study
There is currently no consensus on whether atrial fibrillation (AF) patients at low risk for stroke (one non-sex-related CHA2DS2-VASc point) should be treated with an oral anticoagulant. We conducted a multi-country cohort study in Sweden, Denmark, Norway, and Scotland. In total, 59 076 patients diagnosed with AF at low stroke risk were included. We assessed the rates of stroke or major bleeding during treatment with a non-vitamin K antagonist oral anticoagulant (NOAC), a vitamin K antagonist (VKA), or no treatment, using inverse probability of treatment weighted (IPTW) Cox regression. In untreated patients, the rate for ischaemic stroke was 0.70 per 100 person-years and the rate for a bleed was also 0.70 per 100 person-years. Comparing NOAC with no treatment, the stroke rate was lower [hazard ratio (HR) 0.72; 95% confidence interval (CI) 0.56–0.94], and the rate for intracranial haemorrhage (ICH) was not increased (HR 0.84; 95% CI 0.54–1.30). Comparing VKA with no treatment, the rate for stroke tended to be lower (HR 0.81; 95% CI 0.59–1.09), and the rate for ICH tended to be higher during VKA treatment (HR 1.37; 95% CI 0.88–2.14). Comparing NOAC with VKA treatment, the rate for stroke was similar (HR 0.92; 95% CI 0.70–1.22), but the rate for ICH was lower during NOAC treatment (HR 0.63; 95% CI 0.42–0.94). These observational data suggest that NOAC treatment may be associated with a positive net clinical benefit compared with no treatment or VKA treatment in patients at low stroke risk, a question that can be tested through a randomized controlled trial. In patients with atrial fibrillation at low stroke-risk from Sweden, Denmark, Scotland, and Norway, treatment with a NOAC was associated with a lower stroke rate compared to no treatment and a lower intracranial haemorrhage rate compared to VKA treatment. NOAC, non-vitamin K antagonist oral anticoagulant; VKA, vitamin K antagonist; HR, hazard ratio; VS, versus.
- 10 March 2022
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 43 (37) , 3528-3538
Open AccessOral anticoagulants in patients with atrial fibrillation at low stroke risk: a multicentre observational study
There is currently no consensus on whether atrial fibrillation (AF) patients at low risk for stroke (one non-sex-related CHA2DS2-VASc point) should be treated with an oral anticoagulant. We conducted a multi-country cohort study in Sweden, Denmark, Norway, and Scotland. In total, 59 076 patients diagnosed with AF at low stroke risk were included. We assessed the rates of stroke or major bleeding during treatment with a non-vitamin K antagonist oral anticoagulant (NOAC), a vitamin K antagonist (VKA), or no treatment, using inverse probability of treatment weighted (IPTW) Cox regression. In untreated patients, the rate for ischaemic stroke was 0.70 per 100 person-years and the rate for a bleed was also 0.70 per 100 person-years. Comparing NOAC with no treatment, the stroke rate was lower [hazard ratio (HR) 0.72; 95% confidence interval (CI) 0.56–0.94], and the rate for intracranial haemorrhage (ICH) was not increased (HR 0.84; 95% CI 0.54–1.30). Comparing VKA with no treatment, the rate for stroke tended to be lower (HR 0.81; 95% CI 0.59–1.09), and the rate for ICH tended to be higher during VKA treatment (HR 1.37; 95% CI 0.88–2.14). Comparing NOAC with VKA treatment, the rate for stroke was similar (HR 0.92; 95% CI 0.70–1.22), but the rate for ICH was lower during NOAC treatment (HR 0.63; 95% CI 0.42–0.94). These observational data suggest that NOAC treatment may be associated with a positive net clinical benefit compared with no treatment or VKA treatment in patients at low stroke risk, a question that can be tested through a randomized controlled trial. In patients with atrial fibrillation at low stroke-risk from Sweden, Denmark, Scotland, and Norway, treatment with a NOAC was associated with a lower stroke rate compared to no treatment and a lower intracranial haemorrhage rate compared to VKA treatment. NOAC, non-vitamin K antagonist oral anticoagulant; VKA, vitamin K antagonist; HR, hazard ratio; VS, versus.